cotellic
roche registration gmbh - cobimetinibhemifumarat - melanom - antineoplastiske midler - cotellic er indisert for bruk i kombinasjon med vemurafenib til behandling av voksne pasienter med uoppløselig eller metastatisk melanom med en braf v600 mutasjon.
mektovi
pierre fabre medicament - binimetinib - melanom - antineoplastiske midler - binimetinib i kombinasjon med encorafenib er indisert for behandling av voksne pasienter med inoperabel eller metastatisk melanom med en braf v600 mutasjon.
tagrisso
astrazeneca ab - osimertinib mesilate - karsinom, ikke-småcellet lunge - andre cytostatika, protein kinase hemmere - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.
mektovi 15 mg
2care4 aps - binimetinib - tablett, filmdrasjert - 15 mg
braftovi
pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - antineoplastiske midler - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.
sporanox 100 mg
janssen-cilag as - itrakonazol - kapsel, hard - 100 mg
canizol vet 200 mg
dechra regulatory b.v. - ketokonazol - tablett med smak - 200 mg
atorvastatin pensa 10 mg
pensa pharma ab - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 10 mg
atorvastatin pensa 20 mg
pensa pharma ab - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 20 mg
atorvastatin pensa 40 mg
pensa pharma ab - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 40 mg